Trial Number



Cystic Fibrosis

Participant Age Range

12 years and older

Participant Gender


Enrolling Participants



An Observational Study to Evaluate the Real-world Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor on the Burden of Illness in Cystic Fibrosis Patients

This is a multicenter, observational study with prospective data collection designed to evaluate the real-world burden of illness before and after initiation of treatment with ELX/TEZ/IVA from the CF patient and caregiver-reported perspective. A triple combination (TC) regimen with elexacaftor (ELX), tezacaftor (TEZ), and ivacaftor (IVA) is being developed for the treatment of patients with CF. The pivotal Phase 3 program demonstrated that ELX/TEZ/IVA provides substantial clinical benefit, including improvements in lung function and CF-related quality of life measures in F/MF patients. However, the effectiveness on burden of illness in F/MF patients and the burden on their caregivers in a real-world setting over time is not known. This observational study will evaluate the real-world effectiveness of treatment with ELX/TEZ/IVA on patient burden of illness and caregiver burden, as well as clinical outcomes in the real-world setting.

Related Clinical Trials

Click on the category you are interested in.

Enter Trial number from the area just below the marquee.
How would you prefer to be contacted?
How did you hear about us?
This registration is for:
CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.